2-氟-N-甲氧基-N-甲基烟酰胺 | 949154-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氟-N-甲氧基-N-甲基烟酰胺
• 英文名称: 2-fluoro-N-methoxy-N-methylpyridine-3-carboxamide
• 英文别名: 2-fluoro-N-methoxy-N-methylnicotinamide
• CAS: 949154-26-1
• 化学式: C₈H₉FN₂O₂
• 分子量: 184.17
• InChiKey: IJFAVSQQUDKQDH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氟-N-甲氧基-N-甲基烟酰胺 在 三乙烯二胺 、 正丁基锂 、 一水合肼 作用下， 以 四氢呋喃 、 正己烷 、 甲基叔丁基醚 为溶剂， 反应 2.0h， 生成 3-(3,6-difluoropyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine
  参考文献：
  名称：

  Design and Optimization of Selective Protein Kinase C θ (PKCθ) Inhibitors for the Treatment of Autoimmune Diseases

  摘要：

  Protein kinase C theta (PKC theta) has a central role in T cell activation and survival; however, the dependency of T cell responses to the inhibition of this enzyme appears to be dictated by the nature of the antigen and by the inflammatory environment. Studies in PKC theta-deficient mice have demonstrated that while antiviral responses are PKC theta-independent, T cell responses associated with autoimmune diseases are PKC theta-dependent. Thus, potent and selective inhibition of PKC theta is expected to block autoimmune T cell responses without compromising antiviral immunity. Herein, we describe the development of potent and selective PKC theta inhibitors, which show exceptional potency in cells and in vivo. By use of a structure based rational design approach, a 1000-fold improvement in potency and 76-fold improvement in selectivity over closely related PKC isoforms such as PKC delta were obtained from the initial HTS hit, together with a big improvement in lipophilic efficiency (LiPE).

  DOI：

  10.1021/jm301465a
• 作为产物：
  描述：

  2-氟烟酸 、 二甲羟胺盐酸盐 在 草酰氯 、 N,N-二甲基甲酰胺 、 吡啶 作用下， 以 二氯甲烷 为溶剂， 以3.46 g的产率得到2-氟-N-甲氧基-N-甲基烟酰胺
  参考文献：
  名称：

  [EN] PYRIMIDINE OR PYRIDINE DERIVATES USEFUL AS HCN2 MODULATORS
  [FR] DÉRIVÉS DE PYRIMIDINE OU DE PYRIDINE UTILES EN TANT QUE MODULATEURS DE HCN2

  摘要：

  化合物的公式为(I)，其药学上可接受的盐：其中取代基在规范中定义。这些化合物是超极化激活环核苷酸调节离子通道2（HCN2）的抑制剂。还公开了包含这些化合物的药物组合物，并且这些化合物的用途是治疗或预防由HCN2介导的医学状况，包括神经病痛。

  公开号：

  WO2022185057A1

文献信息

• [EN] TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRAZOLOPYRIDINE KINASE TRICYLIQUE
  申请人：VERTEX PHARMA

  公开号：WO2010011768A1

  公开（公告）日：2010-01-28

  The present invention relates to compounds of the formula (I), which are useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及公式（I）的化合物，其作为蛋白激酶抑制剂具有用途。该发明还提供包含上述化合物的药学上可接受的组合物，并提供使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供制备本发明化合物的方法。
• [EN] PYRAZOLOPYRIDINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOPYRIDINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2010011756A1

  公开（公告）日：2010-01-28

  The present invention relates to compounds of the following formulae, which are useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及以下结构的化合物，可用作蛋白激酶的抑制剂。该发明还提供包含所述化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、症状或紊乱的方法。该发明还提供制备本发明化合物的方法。
• Halogenated sulfonamide derivatives
  申请人：Jubian Vrej

  公开号：US20070213376A1

  公开（公告）日：2007-09-13

  This invention is directed to halogenated sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention. Furthermore, the present invention is directed to use of a compound of the invention for the manufacture of a medicament for treating a subject suffering from depression, anxiety or obesity.

  该发明涉及卤代磺胺衍生物，这些衍生物是NPY Y5受体的配体。该发明提供了一种包含该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明还提供了一种通过混合该发明化合物的治疗有效量和药学上可接受的载体制备的药物组合物。此外，该发明还提供了一种制备药物组合物的方法，包括混合该发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种治疗患有抑郁症的受试者的方法，包括向受试者投与该发明化合物的量。该发明还提供了一种治疗患有焦虑症的受试者的方法，包括向受试者投与该发明化合物的量。该发明还提供了一种治疗患有肥胖症的受试者的方法，包括向受试者投与该发明化合物的量。此外，本发明还涉及使用该发明化合物制造用于治疗患有抑郁症、焦虑症或肥胖症的受试者的药物的用途。
• [EN] SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2022104348A1

  公开（公告）日：2022-05-19

  This invention relates to compounds of Formula I that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及公式I的化合物，其抑制NIK，以及包含这种化合物的制药组合物和使用它们的方法。这些化合物和制药组合物有助于预防或治疗癌症（如B细胞恶性肿瘤，包括白血病，淋巴瘤和骨髓瘤），炎症性疾病，自身免疫性疾病，免疫性皮肤病，如掌跖症和汗腺炎，以及代谢性疾病，如肥胖和糖尿病。
• KINASE INHIBITORS
  申请人：MALTAIS FRANCOIS

  公开号：US20090124602A1

  公开（公告）日：2009-05-14

  The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及用作蛋白激酶抑制剂的化合物。该发明还提供了含有所述化合物的药学上可接受的组合物以及使用这些组合物治疗各种疾病、状况或障碍的方法。该发明还提供了制备本发明化合物的方法。